Prostate Cancer (Immunotherapy)

Animal Model Proves Value of Adjunctive Immunotherapy

Published in Cancer Weekly, January 11th, 2000

by Michelle Marble -- A valuable murine prostate cancer model demonstrated the effectiveness of adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy after primary prostate tumor resection.

Adjuvant therapy is often beneficial after primary tumor resection in many types of cancer. Unfortunately, current adjuvant therapies applied to prostate cancer offer little or no advantage. Research has suggested, however, that adjuvant immunotherapy may have the potential to be beneficial in this disease.

In order to test adjuvant immunotherapies, a predictable and reliable animal model is needed.

Eugene D....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry